Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)

Phase 2

Completed

Conditions: Gastroesophageal Junction Cancer
Stomach Cancer

Interventions: Drug: Docetaxel
Drug: Oxaliplatin
Drug: Calciumfolinat
Drug: 5-Fluorouracil
Biological: Ramucirumab

First Posted Date: 2016-01-25

Last Posted Date: 2022-07-11

Lead Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Target Recruit Count: 180

Registration Number: NCT02661971

Locations: 🇩🇪
Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt, Germany
🇮🇹
Università degli studi della Campania "Luigi Vanvitelli", Napoli, Campania, Italy

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Phase 1

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: BBI608
Drug: 5-FU
Drug: Irinotecan
Drug: Levofolinate
Drug: Bevacizumab

First Posted Date: 2015-12-30

Last Posted Date: 2022-04-12

Lead Sponsor: Sumitomo Pharma Co., Ltd.

Target Recruit Count: 4

Registration Number: NCT02641873

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum

Phase 2

Completed

Conditions: Cancer of Rectum
Rectum Neoplasms
Rectal Cancer
Adenocarcinoma of the Rectum
Cancer of the Rectum
Neoplasm, Rectum
Rectum Cancer

Interventions: Radiation: Radiation
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil

First Posted Date: 2015-12-29

Last Posted Date: 2021-02-18

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 20

Registration Number: NCT02641691

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase 3

Completed

Conditions: Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

Interventions: Drug: Oxaliplatin
Drug: Avelumab
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Capecitabine
Other: Best supportive care

First Posted Date: 2015-12-09

Last Posted Date: 2022-06-09

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 499

Registration Number: NCT02625610

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇦🇺
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
🇫🇷
Centre Georges François Leclerc, Dijon cedex, Côte-d'Or, France

and more 196 locations

BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Biological: Aldesleukin
Biological: Antibody Therapy
Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Biological: Sargramostim

First Posted Date: 2015-12-03

Last Posted Date: 2023-05-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02620865

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Phase 1

Completed

Conditions: Pancreatic Adenocarcinoma

First Posted Date: 2015-12-03

Last Posted Date: 2018-09-13

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 11

Registration Number: NCT02620423

Locations: 🇺🇸
Cancer Therapy & Research Center at UTHSCSA, San Antonio, Texas, United States

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: AZD0156
Drug: Olaparib
Drug: irinotecan
Drug: Fluorouracil
Drug: Folinic Acid

First Posted Date: 2015-10-27

Last Posted Date: 2022-09-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 84

Registration Number: NCT02588105

Locations: 🇬🇧
Research Site, Manchester, United Kingdom

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Irinotecan
Drug: Oxaliplatin

First Posted Date: 2015-10-21

Last Posted Date: 2017-03-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT02582970

Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Phase 3

Completed

Conditions: Gastric Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Docetaxel
Drug: Trastuzumab
Drug: sodium folinate
Procedure: Surgery

First Posted Date: 2015-10-16

Last Posted Date: 2024-11-12

Lead Sponsor: Krankenhaus Nordwest

Target Recruit Count: 183

Registration Number: NCT02578368

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt am Main, Germany

Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Colon Adenocarcinoma
Metastatic Pancreatic Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreatic Ductal Adenocarcinoma
Rectal Adenocarcinoma
Stage III Pancreatic Cancer
Stage IVA Rectal Cancer
Stage IIIA Colon Cancer
Stage IIIB Colon Cancer
Stage IIIC Colon Cancer

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Oxaliplatin
Drug: pan FGFR Kinase Inhibitor BGJ398
Other: Pharmacological Study

First Posted Date: 2015-10-14

Last Posted Date: 2016-05-20

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02575508

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy